Bacigalupo, Andrea
 Distribuzione geografica
Continente #
NA - Nord America 2.486
EU - Europa 2.136
AS - Asia 1.387
SA - Sud America 51
AF - Africa 31
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 4
Totale 6.107
Nazione #
US - Stati Uniti d'America 2.448
SE - Svezia 611
CN - Cina 574
IT - Italia 530
SG - Singapore 388
DE - Germania 190
IE - Irlanda 188
ID - Indonesia 156
FR - Francia 138
TR - Turchia 128
RU - Federazione Russa 89
FI - Finlandia 79
GB - Regno Unito 72
UA - Ucraina 63
PL - Polonia 56
IN - India 54
BR - Brasile 31
CA - Canada 28
BE - Belgio 23
CI - Costa d'Avorio 20
HK - Hong Kong 18
AT - Austria 17
JP - Giappone 16
CZ - Repubblica Ceca 14
IR - Iran 14
NL - Olanda 14
AU - Australia 12
ES - Italia 10
KR - Corea 10
MX - Messico 8
TW - Taiwan 7
EG - Egitto 6
RO - Romania 6
AR - Argentina 5
CH - Svizzera 5
CO - Colombia 5
DK - Danimarca 5
CL - Cile 4
PT - Portogallo 4
HU - Ungheria 3
PH - Filippine 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BG - Bulgaria 2
DZ - Algeria 2
EC - Ecuador 2
EU - Europa 2
HR - Croazia 2
IL - Israele 2
KG - Kirghizistan 2
LI - Liechtenstein 2
LT - Lituania 2
MA - Marocco 2
NO - Norvegia 2
UZ - Uzbekistan 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
EE - Estonia 1
GR - Grecia 1
IM - Isola di Man 1
JM - Giamaica 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MK - Macedonia 1
MY - Malesia 1
NP - Nepal 1
PE - Perù 1
PK - Pakistan 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
VE - Venezuela 1
VN - Vietnam 1
Totale 6.107
Città #
Chandler 555
Singapore 285
Dublin 186
Ashburn 168
Jakarta 153
Ann Arbor 119
Izmir 118
Wilmington 104
Nanjing 98
Milan 87
Rome 82
Beijing 79
San Mateo 74
Moscow 71
Jacksonville 69
Fairfield 65
Boston 59
Cattolica 56
Houston 53
Nanchang 53
Princeton 53
Warsaw 52
Florence 47
New York 42
Seattle 39
Dearborn 38
Lawrence 36
Los Angeles 36
Redwood City 36
Marseille 34
Woodbridge 33
Boardman 32
Fuzhou 32
Helsinki 32
Hebei 23
Bremen 22
Brussels 22
Kunming 22
Redmond 22
Cambridge 21
Abidjan 20
Chicago 20
Jiaxing 20
Shenyang 20
Munich 19
Paris 19
Changsha 18
Hangzhou 18
Lancaster 18
Shanghai 18
Guangzhou 17
Mountain View 16
Tianjin 16
Nuremberg 15
Pune 15
Arezzo 13
Hong Kong 13
Toronto 13
Brno 11
Council Bluffs 11
London 11
Santa Clara 11
Turin 11
Washington 11
Bologna 10
Lappeenranta 10
Mcallen 9
Norwalk 9
Zhengzhou 9
Andover 8
Hefei 8
Seoul 8
Falkenstein 7
Frankfurt am Main 7
Ottawa 7
São Paulo 7
Worcester 7
Edinburgh 6
Phoenix 6
Vienna 6
Augusta 5
Barcelona 5
Bogotá 5
Kiel 5
Lanzhou 5
Naples 5
Nürnberg 5
Bagnacavallo 4
Catania 4
Clearwater 4
Colli del Tronto 4
Jinan 4
Karasawa 4
Mexico City 4
Modena 4
Napoli 4
Newark 4
Parma 4
Sant'Egidio alla Vibrata 4
Taipei 4
Totale 3.793
Nome #
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial 315
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies:uptade consensus recommendations of the European Society for Blood 223
Rabbit ATG/ATLG in preventing graft-versus-host disease after allogenic stem cell transplantation: consensus-besed recommendations by an international expert panel 177
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 87
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 84
Nasopharynxkarzinom in einem europäischen Gebiet mit geringer Inzidenz: Eine prospektive Beobachtungsanalyse der Kopf- und Hals-Studiengruppe der Italienischen Gesellschaft für Radioonkologie (AIRO) 81
Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation. 78
UGT1A1 Polymorphism and Mortality Outcome after Allogeneic Stem Cell Transplantation with Busulfan Based Regimen 77
A closer look at permissive HLA mismatch 76
Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers 75
Alternative donor transplants for severe aplastic anemia: current experience 73
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study 73
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 72
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study 71
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 71
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 70
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 69
Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal 69
ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- And Long-term Outcomes 69
Unrelated cord blood transplantation and post-transplant cyclophosphamide 68
Bone marrow haploidentical transplant with post-transplantation cyclophosphamide :does graft cell content have an impact on main clinical outcomes? 68
Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia 67
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 67
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 65
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 65
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD 64
Integrating transplantation with antibodies and genetically modified T-cell therapies 64
Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation 64
Unrelated cord blood transplantation and post-transplant cyclophosphamide 64
Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant 63
Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature 63
Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? 62
Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia 62
Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia 62
Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes? 62
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 62
Antithymocyte globulin in the conditioning regimen: why not? 60
Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups 59
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome 59
Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: A registry study by the European society for blood and marrow transplantation 59
Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression 58
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 58
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome 57
Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single-centre experience 57
Menstrual patterns, fertility and main pregnancy outcomes after allogeneic haematopoietic stem cell transplantation 56
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation 55
Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: A retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation 55
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: A retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) 54
Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation 54
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: A report from the acute leukemia working party of the EBMT 53
Alternative donor transplants for severe aplastic anemia: Current experience 53
Failure to effectively treat chronic graft-versus-host disease: a strong call for prevention 52
Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis 52
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation 52
CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation 52
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study 51
RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT 50
Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients 50
PURLs: Light therapy for nonseasonal major depressive disorder? 49
Post-transplant cyclophosphamide versus antithymocyte-globulin as graft versus host disease prophylaxis in haploidentical transplant 48
Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis 47
Allogeneic stem cell transplantation for nonmalignant diseases 47
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation 47
Severe cmv infection after chemo-immunotherapy with dose- reduced bendamustine and rituximab in a mantle cell lymphoma old patient 47
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 46
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study 46
Days alive outside hospital and readmissions in patients undergoing allogeneic transplants from identical siblings or alternative donors 46
Failure to effectively treat chronic graft-versus-host disease: A strong call for prevention 45
Reducing infectious complications after allogeneic stem cell transplant 45
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All-Trans Retinoic Acid: A Monocentric Experience 44
Long-term survival in a patient with head and neck paraganglioma treated with tailored modalities for 20 years: a case report 44
Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet 44
Time to surgery and pathologic complete response after neoadjuvant chemoradiation in rectal cancer: A population study on 2094 patients 44
Second haploidentical stem cell transplantation for primary graft failure 44
Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation 43
full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment 43
First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012 41
Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single-centre experience 39
HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide 38
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 38
HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide 36
Steroid treatment of acute graft-versus-host disease grade I: A randomized trial 36
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 35
Extending long term follow up of patient with acute myeloid leukemia after autologous stem cell transplantation: Disclosing late mortality and causes of death 35
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 33
Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML 33
Haploidentical bone marrow transplantation for AML in remission following TBF conditioning: a long-term follow up 33
How I treat acquired aplastic anemia 32
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT 32
Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. 32
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 29
Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study 29
impact of donor age and kinship on clinical outcomes after T cell-replete haploidentical transplantation with PT-Cv 28
The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation 25
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy 25
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 24
Acute graft versus host disease 1976-2020: reduced incidence and predictive factors 24
Peripheral Blood Allogeneic Stem Cell Mobilization: Can We Predict a Suboptimal Mobilization? 24
Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants 24
THE IMPACT OF EDUCATION ON PATIENTS' PSYCHOEMOTIONAL STATUS DURING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTRE PROSPECTIVE STUDY BY THE GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO 23
Totale 5.775
Categoria #
all - tutte 40.154
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.154


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020272 0 0 0 0 0 0 0 18 28 92 82 52
2020/2021402 43 51 7 17 54 37 18 9 60 24 65 17
2021/2022744 72 12 31 31 49 15 15 116 49 72 129 153
2022/20231.746 260 228 137 243 140 215 79 117 169 50 85 23
2023/20241.169 41 262 66 63 35 115 80 83 39 82 133 170
2024/2025911 74 84 212 119 184 87 103 48 0 0 0 0
Totale 6.352